Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
Caroline Pothet, Head of advanced therapies and haemato-oncology at the European Medicines Agency, shared a post on LinkedIn:
“Sickle cell disease and thalassaemia remain areas of significant unmet medical need. Advancing treatment options starts with supporting robust, innovative medicine development.
The release of two new EMA draft guidelines is an important step towards this goal, helping guide the development of new treatments for patients who need them. Thanks to Caroline Voltz Girolt and both drafting groups for driving this.
This is your turn to contribute by reviewing the guidelines and sharing your feedback:
Draft guideline on sickle cell disease
Draft guideline on thalassaemia
The public consultation is open until 31 January 2027.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience